This commentary reviews top advances in hepatobiliary cancer research in 2021-2022, focusing on leveraging immunotherapeutics in combination with other therapies earlier in the disease course and targeted to patient's individualized biomarkers that may predict response or resistance to checkpoint inhibitors.
Keywords: biliary tract cancer; biomarker studies; checkpoint inhibitors; cholangiocarcinoma; correlative studies; hepatocellular carcinoma; immunotherapy; liver cancer; neoadjuvant therapy.
Published 2023. This article is a U.S. Government work and is in the public domain in the USA.